Following Vijay Kumar’s exit, acting CBER Director Karim Mikhail will also oversee a review office that has become a battleground for debates on FDA flexibility.
An article from
Dive Brief
Following Vijay Kumar’s exit, acting CBER Director Karim Mikhail will also oversee a review office that has become a battleground for debates on FDA flexibility.
Published June 30, 2026
The Food and Drug Administration has seen substantial turnover among its top drug review officials during the Trump administration.
Vijay Kumar, FDA's acting OTP director, says he's stepping down for reasons unrelated to agency turmoil, as the White House also…
The departure of Vijay Kumar follows a broader leadership shakeup at the FDA.
The U.S. Food and Drug Administration is shuffling its top drug and biologics regulators, days after the departure of former…
Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted…
Vinay Prasad is leaving his post as director of the Center for Biologics Evaluation and Research.
The U.S. Food and Drug Administration's drug center sees a leadership change as acting head Tracy Beth Hoeg departs, replaced by…
